Arthur ("Art") Cohn is an IP and life sciences transactions attorney and has practiced law in the life sciences industry for almost 30 years.  Art is a corporate lawyer with a broad-based transactional practice with extensive experience in structuring and negotiating US and global licenses, research, development and commercial collaborations, M&A and other strategic transactions at all stages in the biotech, small molecule, vaccines, consumer products and nutritionals areas.  Art brings to his practice extensive experience and insights developed over 25 years as in-house counsel with major global pharmaceutical companies.  

Prior to joining DLA, Art was Vice President and Assistant General Counsel at Pfizer where he was a trusted legal and business advisor to senior management and other client stakeholders, with a focus on Pfizer’s complex licensing and collaboration transactions and alliances.  Art also led Pfizer’s legal team supporting global procurement and operations, advising management and client stakeholders regarding day-to-day commercial and corporate matters.  Prior to Pfizer’s acquisition of Wyeth, Art was chief counsel for Wyeth’s Global Business Development group and led the legal group with responsibility for advising Wyeth’s pharmaceuticals and research businesses on a wide range of transactional matters.